Raymond James Financial Services Advisors, Inc. Fate Therapeutics Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$3.54 - $8.35 $78,018 - $184,025	22,039 New	22,039 $161,000
Q2 2021 Aug 11, 2021	SELL	$67.25 - $92.52 $267,856 - $368,507	-3,983 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$72.16 - $117.4 $3,102 - $5,048	43 Added 1.09%	3,983 $328,000
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $150,074 - $397,743	3,940 New	3,940 $358,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$21.9 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$17.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$16.8 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$9.25 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$8.72 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account